CDK 4/6 inhibitors for hormone receptor-positive breast cancer may cause cardiovascular toxicity, but evidence and mechanism data remain limited.
What are the cardiovascular toxicities and related mechanisms caused by CDK 4/6 inhibitors in patients with advanced breast cancer?
This review summarizes the potential cardiovascular toxicities and underlying mechanisms associated with CDK 4/6 inhibitors used in the treatment of advanced breast cancer.
Absolute Event Rate: 0% vs 0%
Breast cancer is the most common malignant tumour in women, and it has a high incidence and mortality rate both in the world and in China. Hormone receptor-positive breast cancer accounts for about 60–70% of breast cancer and is the most common subtype of advanced breast cancer. Cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors in combination with endocrine therapy have emerged as the treatment of choice for hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer. Emergence inhibitors of CDK 4/6 have significantly improved outcomes in patients with hormone receptor-positive advanced breast cancer. It is an indisputable fact that cardiotoxicity caused by breast cancer treatment can have a significant impact on the quality of life of cancer survivors; however, there are few studies on the cardiovascular toxicity of CDK 4/6 inhibitors. This article reviews the cardiovascular toxicity and related mechanisms that may be caused by CDK 4/6 inhibitors.
Zhang et al. (Mon,) reported a other. CDK 4/6 inhibitors for hormone receptor-positive breast cancer may cause cardiovascular toxicity, but evidence and mechanism data remain limited.